125 related articles for article (PubMed ID: 37706534)
1. In Reply to "Pathogenic/Likely Pathogenic Somatic CDK12 Mutations in Black Men With Prostate Cancer".
Valle LF; Nickols NG; Yamoah K; Garraway IP; Maxwell KN; Lynch JA
Oncologist; 2023 Nov; 28(11):e1129-e1130. PubMed ID: 37706534
[TBL] [Abstract][Full Text] [Related]
2. Pathogenic/Likely Pathogenic Somatic CDK12 Mutations in Black Men With Prostate Cancer.
Sartor O; Jang A; Ledet E
Oncologist; 2023 Nov; 28(11):e1127-e1128. PubMed ID: 37589230
[TBL] [Abstract][Full Text] [Related]
3. Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced Prostate Cancer.
Reimers MA; Yip SM; Zhang L; Cieslik M; Dhawan M; Montgomery B; Wyatt AW; Chi KN; Small EJ; Chinnaiyan AM; Alva AS; Feng FY; Chou J
Eur Urol; 2020 Mar; 77(3):333-341. PubMed ID: 31640893
[TBL] [Abstract][Full Text] [Related]
4. Prognostic and clinicopathological value of CDK12 mutation in prostate cancer: a meta-analysis.
Zhang W; Zhou L; Di J
Expert Rev Anticancer Ther; 2023 Feb; 23(2):207-216. PubMed ID: 36734254
[TBL] [Abstract][Full Text] [Related]
5.
Warner E; Herberts C; Fu S; Yip S; Wong A; Wang G; Ritch E; Murtha AJ; Vandekerkhove G; Fonseca NM; Angeles A; Beigi A; Schönlau E; Beja K; Annala M; Khalaf D; Chi KN; Wyatt AW
Clin Cancer Res; 2021 Mar; 27(6):1650-1662. PubMed ID: 33414135
[TBL] [Abstract][Full Text] [Related]
6. CDK12 Gene Alterations in Prostate Cancer: Present, but Clinically Actionable?
Marciscano AE; Barbieri CE
Eur Urol; 2020 Nov; 78(5):680-681. PubMed ID: 32381460
[No Abstract] [Full Text] [Related]
7. Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer.
Wu YM; Cieślik M; Lonigro RJ; Vats P; Reimers MA; Cao X; Ning Y; Wang L; Kunju LP; de Sarkar N; Heath EI; Chou J; Feng FY; Nelson PS; de Bono JS; Zou W; Montgomery B; Alva A; ; Robinson DR; Chinnaiyan AM
Cell; 2018 Jun; 173(7):1770-1782.e14. PubMed ID: 29906450
[TBL] [Abstract][Full Text] [Related]
8. Pan-cancer Analysis of CDK12 Alterations Identifies a Subset of Prostate Cancers with Distinct Genomic and Clinical Characteristics.
Nguyen B; Mota JM; Nandakumar S; Stopsack KH; Weg E; Rathkopf D; Morris MJ; Scher HI; Kantoff PW; Gopalan A; Zamarin D; Solit DB; Schultz N; Abida W
Eur Urol; 2020 Nov; 78(5):671-679. PubMed ID: 32317181
[TBL] [Abstract][Full Text] [Related]
9. Characterizing cyclin-dependent kinase 12(CDK12)-altered aggressive prostate cancer: a twelve-case series.
Iwasawa T; Kosaka T; Yasumizu Y; Hongo H; Yanai Y; Baba Y; Matsumoto K; Nakamura K; Nishihara H; Oya M
Int J Clin Oncol; 2022 Dec; 27(12):1867-1873. PubMed ID: 36271301
[TBL] [Abstract][Full Text] [Related]
10. A novel germline EGFR variant p.R831H causes predisposition to familial CDK12-mutant prostate cancer with tandem duplicator phenotype.
Qian K; Wang G; Ju L; Liu J; Luo Y; Wang Y; Peng T; Chen F; Zhang Y; Xiao Y; Wang X
Oncogene; 2020 Oct; 39(44):6871-6878. PubMed ID: 32978518
[TBL] [Abstract][Full Text] [Related]
11. Germline and somatic DNA repair gene alterations in prostate cancer.
Dall'Era MA; McPherson JD; Gao AC; DeVere White RW; Gregg JP; Lara PN
Cancer; 2020 Jul; 126(13):2980-2985. PubMed ID: 32315455
[TBL] [Abstract][Full Text] [Related]
12. CDK12 and HER2 coamplification in two urothelial carcinomas with rapid and aggressive clinical progression.
Yanai Y; Kosaka T; Nakamura K; Aimono E; Matsumoto K; Morita S; Mikami S; Nishihara H; Oya M
Cancer Sci; 2020 Dec; 111(12):4652-4655. PubMed ID: 33038052
[TBL] [Abstract][Full Text] [Related]
13. Human CDK12 and CDK13, multi-tasking CTD kinases for the new millenium.
Greenleaf AL
Transcription; 2019 Apr; 10(2):91-110. PubMed ID: 30319007
[TBL] [Abstract][Full Text] [Related]
14. CDK12 Mutation in Advanced Prostate Cancer: A Marker for Clinical Subtype?
Wang X; Chen H; Luo J; Xie L
Eur Urol; 2020 Mar; 77(3):342-343. PubMed ID: 31694772
[No Abstract] [Full Text] [Related]
15. Comparison of circulating tumor DNA between African American and Caucasian patients with metastatic castrate-resistant prostate cancer post-abiraterone and/or enzalutamide.
Jang A; Lanka SM; Huang M; Casado CV; Caputo SA; Sweeney PL; Gupta K; Pocha O; Habibian N; Hawkins ME; Lieberman AD; Schwartz J; Jaeger EB; Miller PJ; Layton JL; Barata PC; Lewis BE; Ledet EM; Sartor O
Prostate; 2023 Aug; 83(11):1028-1034. PubMed ID: 37113064
[TBL] [Abstract][Full Text] [Related]
16. Differential treatment outcomes in BRCA1/2-, CDK12-, and ATM-mutated metastatic castration-resistant prostate cancer.
Kwon DH; Chou J; Yip SM; Reimers MA; Zhang L; Wright F; Dhawan MS; Borno HT; Desai A; Aggarwal RR; Wyatt AW; Small EJ; Alva AS; Chi KN; Feng FY; Koshkin VS
Cancer; 2021 Jun; 127(12):1965-1973. PubMed ID: 33690902
[TBL] [Abstract][Full Text] [Related]
17. Actionable Genomic Alterations in Prostate Cancer Among Black and White United States Veterans.
Valle LF; Nickols NG; Hausler R; Alba PR; Anglin-Foote T; Perez C; Yamoah K; Rose BS; Kelley MJ; DuVall SL; Garraway IP; Maxwell KN; Lynch JA
Oncologist; 2023 Jun; 28(6):e473-e477. PubMed ID: 37084789
[TBL] [Abstract][Full Text] [Related]
18.
Lotan TL; Antonarakis ES
Clin Cancer Res; 2021 Jan; 27(2):380-382. PubMed ID: 33199495
[TBL] [Abstract][Full Text] [Related]
19. CRISPR screening identifies CDK12 as a conservative vulnerability of prostate cancer.
Lei H; Wang Z; Jiang D; Liu F; Liu M; Lei X; Yang Y; He B; Yan M; Huang H; Liu Q; Pang J
Cell Death Dis; 2021 Jul; 12(8):740. PubMed ID: 34315855
[TBL] [Abstract][Full Text] [Related]
20. Predicted Immunogenicity of CDK12 Biallelic Loss-of-Function Tumors Varies across Cancer Types.
Elliott A; Zhang J; Zhang Q; Swensen J; Martin D; Xiu J; Geynisman DM; Vaena D; Herzog TJ; Holloway RW; El-Deiry WS; Spetzler D; Heath E; Stafford P; Korn WM
J Mol Diagn; 2021 Dec; 23(12):1761-1773. PubMed ID: 34562615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
